Q2 EPS Forecast for Nektar Therapeutics Reduced by Analyst

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Nektar Therapeutics in a research note issued to investors on Monday, July 7th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($3.43) per share for the quarter, down from their previous forecast of ($2.55). B. Riley currently has a "Buy" rating and a $85.00 target price on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. B. Riley also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.89) EPS, Q4 2025 earnings at ($3.06) EPS, FY2025 earnings at ($11.11) EPS, FY2026 earnings at ($11.61) EPS, FY2027 earnings at ($14.17) EPS, FY2028 earnings at ($12.89) EPS and FY2029 earnings at ($11.64) EPS.

A number of other equities research analysts have also weighed in on the stock. BTIG Research upped their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and increased their price objective for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. HC Wainwright raised their target price on Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. Wall Street Zen downgraded Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. Finally, William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $88.33.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock traded down $0.09 during trading hours on Thursday, reaching $25.01. The company's stock had a trading volume of 1,207,020 shares, compared to its average volume of 504,145. The company has a market capitalization of $310.37 million, a P/E ratio of -2.61 and a beta of 0.94. The stock's fifty day simple moving average is $14.22 and its two-hundred day simple moving average is $12.89. Nektar Therapeutics has a one year low of $6.48 and a one year high of $37.38.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. During the same quarter last year, the firm posted ($2.70) EPS.

Hedge Funds Weigh In On Nektar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Nektar Therapeutics by 12.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company's stock valued at $680,000 after acquiring an additional 80,034 shares during the last quarter. Monaco Asset Management SAM grew its stake in Nektar Therapeutics by 1.8% in the 4th quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company's stock valued at $1,891,000 after purchasing an additional 35,648 shares during the period. Sei Investments Co. increased its position in shares of Nektar Therapeutics by 50.6% during the 4th quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company's stock valued at $88,000 after purchasing an additional 31,654 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Nektar Therapeutics by 29.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company's stock worth $1,100,000 after purchasing an additional 269,695 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Nektar Therapeutics by 10.4% during the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock worth $486,000 after purchasing an additional 49,319 shares during the period. Hedge funds and other institutional investors own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.